戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es were in grades requiring a second dose of measles vaccine.
2 s seroconverted after receiving two doses of measles vaccine.
3 of life, which affects the immunogenicity of measles vaccine.
4 come countries (LMICs), missing out on their measles vaccine.
5 re commonly administered in combination with measles vaccine.
6 quence of previous exposure to the pediatric measles vaccine.
7 ne but not, a live-attenuated viral vaccine, measles vaccine.
8 efore the introduction and widespread use of measles vaccine.
9 ide despite the availability of an effective measles vaccine.
10 who were eligible to receive a first dose of measles vaccine.
11  ratios (HRRs) for measles vaccine versus no measles vaccine.
12 ussis vaccine dose 1 (DTP1), DTP2, DTP3, and measles vaccine.
13 receive the current licensed live attenuated measles vaccine.
14  into the ontogeny of the immune response to measles vaccine.
15 ung to receive currently licensed attenuated measles vaccines.
16 nuated measles virus are in use worldwide as measles vaccines.
17 lly worldwide before the introduction of the measles vaccines.
18 hs; 8 weeks-4 months; 12 weeks-6 months) and measles vaccine (38 weeks-12 months).
19  subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier.
20                    One month after the first measles vaccine, 42.3% of HU and 46.4% of HEU children w
21 ly significant effect on immune responses to measles vaccine; 61 of 970 (6.3%) children who received
22  lowest if IPV is administered with DTP3 and measles vaccine (69%) and highest if administered with D
23                             After 2 doses of measles vaccine, 98.2% of all subjects in this study wer
24                               The demand for measles vaccine across populations driven by individual
25 in 70 children aged 5-10 years after primary measles vaccine administered at 6, 9, or 12 months.
26 tudy of the immunogenicity of standard-titer measles vaccine administered at 9 months of age to HIV-1
27  receive measles vaccine at 4.5 months or no measles vaccine; all children were offered measles vacci
28 ported evidence of reduced immunogenicity of measles vaccine among HIV-infected children, supporting
29             For example, the live attenuated measles vaccine and BCG vaccine may reduce mortality fro
30 infants when administered concomitantly with measles vaccine and PsA-TT.
31  inbred cotton rats which were infected with measles vaccine and wild-type viruses.
32 ine (DPT3) and those who were immunized with measles vaccine, and comparing their values to those obt
33 en a national goal since the introduction of measles vaccine, and measles surveillance has been cruci
34  estimate effectiveness of Romanian-produced measles vaccine, and to evaluate age at vaccination and
35               For some vaccines, such as the measles vaccine, antibodies serve as the correlate of pr
36 h a Vi-conjugate vaccine coadministered with measles vaccine are planned.
37 agnostic tests are available, and attenuated measles vaccines are effective and immunogenic.
38 ed infants to this problem, more immunogenic measles vaccines are highly desirable.
39 the introduction of a second routine dose of measles vaccine as a combined measles-mumps-rubella (MMR
40         This study uses a safe and effective measles vaccine as a platform for vaccination against SA
41 g viral vaccine using the highly efficacious measles vaccine as vector, a promising technology with p
42 ccine candidate using the highly efficacious measles vaccine as vector, a technology which has proved
43 is vaccine were randomly assigned to receive measles vaccine at 4.5 months or no measles vaccine; all
44 sing serum samples from infants who received measles vaccine at 6 months of age and measles-mumps-rub
45 recommendation to administer a first dose of measles vaccine at 6 months of age to HIV-infected child
46 rubella (MMR)-II at 12 months of age (n=26), measles vaccine at 9 months of age and measles-mumps-rub
47 o measles vaccine; all children were offered measles vaccine at 9 months of age.
48      Fifty-five infants were vaccinated with measles vaccine at age 6 (n=32) or 9 (n=23) months, foll
49                            Children received measles vaccine at age 9 months and measles-rubella vacc
50                                  One dose of measles vaccine at age 9 months was highly immunogenic.
51  visit among the children who had received a measles vaccine at inclusion.
52 nicity of 2 vaccination regimens: monovalent measles vaccine (Attenuvax) at 6 months of age and measl
53 from 1992 onwards (year of public nationwide measles vaccine availability).
54   These findings support WHO guidelines that measles vaccine be administered to potentially susceptib
55 est that administration of the first dose of measles vaccine before 15 months of age may not be optim
56 dation that countries reach 80% coverage for measles vaccine before introducing rubella vaccination,
57 ine, three doses of pentavalent vaccine, and measles vaccine) by 12 months of age constituted the pri
58 on has on immune responses to measles and to measles vaccine can impact measles elimination efforts.
59 ar immunisation with a candidate recombinant measles vaccine carrying an HIV-1 insert encoding Clade
60 y-reported values, the immunogenicity of the measles vaccine component was unexpectedly low (75% (95%
61  incidence decreased rapidly with increasing measles vaccine coverage and became low or negligible wh
62 sles in 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every
63                                   The gap in measles vaccine coverage between white and nonwhite chil
64                                        While measles vaccine coverage has increased markedly, signifi
65 that each country in the subregion maintains measles vaccine coverage of >/=95%.
66             The model-based estimate of true measles vaccine coverage was 61.1% (95% credible interva
67 d subgroup analyses by country income level, measles vaccine coverage, and measles incidence.
68     We also examined data on routine and SIA measles vaccine coverage, measles case-based surveillanc
69 er with respect to median routine first-dose measles vaccine coverage, median coverage for 3 measles
70 BRs, and measles serology and estimated true measles vaccine coverage.
71 atened by failure to maintain high levels of measles vaccine coverage.
72 macaques immunized with formalin-inactivated measles vaccine developed transient neutralizing and fus
73                        Thus, live attenuated measles vaccines differ in replicative capacity and path
74 patients, a 9-yr-old boy in Iran with severe measles vaccine disease at 1 yr and a 14-yr-old girl in
75 sed on earlier administration of their first measles vaccine dose at </=12 vs >/=15 months of age.
76            Among 5542 children given a first measles vaccine dose at 11, 12, 13-14, and 15-22 months
77 nicity data among children given their first measles vaccine dose between 11 and 22 months of age wer
78     Negative effects of earlier age at first measles vaccine dose persisted after the second dose.
79 ight blunt the immune response to subsequent measles vaccine doses.
80 n, highlighting the importance of additional measles vaccine doses.
81  not respond reliably to the live attenuated measles vaccine due the immaturity of their immune syste
82                               Information on measles vaccine effectiveness (VE) is critical to help i
83 es (ARs) by vaccination status and estimated measles vaccine effectiveness as 1 - [ARvaccinated/ARunv
84 Ws) by assessing laboratory characteristics, measles vaccine effectiveness, and serological correlate
85 y was deficient in 6-month-old infants given measles vaccine, even in the absence of detectable passi
86         In the 1960s, a formalin-inactivated measles vaccine (FIMV) predisposed recipients to atypica
87 ated with LAV or with a formalin-inactivated measles vaccine (FIMV).
88 erage for both the first and second doses of measles vaccine for all local populations; developing de
89 jecting polio vaccine, 38% of mothers sought measles vaccine for their children.
90 measles viruses (MV) expressing HBsAg retain measles vaccine function in monkeys but do not induce a
91                    Following enrollment, the measles vaccine group had an admission HRR of 0.70 (95%
92                        In the United States, measles vaccine has been given at age 12 to 15 months to
93 ials from low-income countries indicate that measles vaccine has beneficial nonspecific effects, prot
94 T cell responses important for evaluation of measles vaccines, human leukocyte antigen (HLA)-A2-posit
95              Cytokines are key regulators of measles vaccine humoral and cellular immunity.
96 vidence regarding measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in
97  the United States since the introduction of measles vaccine in 1963.
98  to evaluate the long-term immunogenicity of measles vaccine in a sample of medical students and resi
99            Avidity and isotype maturation of measles vaccine-induced antibody are affected by age, pr
100 ces in cytokine levels should also influence measles vaccine-induced immunity.
101 Ps in the IL-2, IL-10, and IL-12RB genes and measles vaccine-induced immunity.
102 .001), whereas GMCs increased with older age measles vaccine initiation (P < .001).
103                            Several potential measles vaccine innovations are in development to addres
104                                      Because measles vaccine is delivered by injection, hurdles to hi
105                          The live attenuated measles vaccine is extremely effective in preventing mea
106 dose measles immunization schedule, in which measles vaccine is given at 12 and 18 months of age, had
107                      Third, a second dose of measles vaccine is needed to achieve satisfactory levels
108                                        Early measles vaccine may have major benefits for infant morbi
109                          Continuation of the measles vaccine (MV) after eradication could still reduc
110            Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies hav
111 th Organization recommends administration of measles vaccine (MV) at age 9 months in low-income count
112 y demonstrated the efficacy of a recombinant measles vaccine (MV) expressing the secreted form of the
113                                              Measles vaccine (MV) has a greater effect on child survi
114 paigns with vitamin A supplementation (VAS), measles vaccine (MV), and H1N1 influenza vaccine.
115 inst nonvaccine infections, as described for measles vaccine (MV), or increased susceptibility to inf
116 pertussis (DTP) is often given with or after measles vaccine (MV)-out of sequence.
117 n had been allocated 1:1 to a second dose of measles vaccine (MV2) at 18 months of age or to no vacci
118 single unit dose, dry powder live-attenuated measles vaccine (MVDP) for respiratory delivery without
119 primarily in developed countries) shows that measles vaccine performs in these settings as anticipate
120                      It is not known whether measles vaccine protects against hospital admissions.
121                In low-income countries, live measles vaccine reduces mortality from causes other than
122 immunogenicity and safety of an early 2-dose measles vaccine regimen administered at 6 and 12 months
123 rtality support the study of an early 2-dose measles vaccine regimen.
124 ms involved in the attenuation of individual measles vaccines remain to be elucidated, in vitro assay
125          After the first and second doses of measles vaccine, respectively, the percentages of childr
126 atitis virus, alphavirus-based chimeras, and measles vaccine Schwarz strain (MV/Schw) have been descr
127 t a 10% threshold for CHE, the first dose of measles vaccine stood out in averting around 1,400 CHE c
128 a rapid, easily adoptable method to identify measles vaccine strains in suspect cases.
129 uantitative PCR [RT-qPCR]) that can identify measles vaccine strains rapidly, with high throughput, a
130          The complete genomic sequences of 9 measles vaccine strains were compared with the sequence
131 iting a cell-mediated immune response in new measles vaccine strategies.
132                               Pursuing a new measles vaccine strategy that might be effective in youn
133 ome of interest was serological responses to measles vaccine, stratified by HIV infection status.
134  bias were also lower when using results for measles vaccine than for DPT3, suggesting that the measl
135 dies were more likely to have never received measles vaccine than those with antibodies (adjusted OR
136 hat the discrepancy between the coverages of measles vaccine that are driven by self-interest and tho
137                        There is a need for a measles vaccine that can be administered at birth in the
138 en showed good primary antibody responses to measles vaccine, their rapid waning of antibody suggests
139 stagnating global coverage with two doses of measles vaccine through advocacy, education, and the str
140 re being investigated as a new generation of measles vaccine to protect infants too young to receive
141 me highlights the transition from monovalent measles vaccine to the incorporation of measles-mumps-ru
142  2017 regulation, which consists of offering measles vaccine to the parents of children who get vacci
143 ied as measles cases; 6 were vaccinated with measles vaccine twice, 1 was vaccinated once, and 1 was
144 ding admission hazard rate ratios (HRRs) for measles vaccine versus no measles vaccine.
145 ted by immunization with the live attenuated measles vaccine virus.
146 s, the estimated effectiveness of 2 doses of measles vaccine was 52% (95% confidence interval [CI], -
147                  Both studies indicated that measles vaccine was highly effective.
148                                   Monovalent measles vaccine was introduced in 1977, and measles vacc
149 dy seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmuni
150 ith antibody titers >120 mIU after the first measles vaccine were lower in infants vaccinated at age
151 tudies suggest that vaccination with BCG and measles vaccines were associated with a reduced risk of
152 ility that immunisation with live attenuated measles vaccine, which induces active immunity to measle
153 ore, the specific proteins included in a new measles vaccine will affect the type of cytokine respons
154 tates, partly because of the assumption that measles vaccines will continue to be delivered in respon

 
Page Top